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Abstract
“No virus, no transmission.” Studies have repeatedly shown that viral load (the quantity of virus present in blood
and sexual secretions) is the strongest predictor of HIV transmission during unprotected sex or transmission from
infected mother to child.
Effective treatment lowers viral load to undetectable levels. If one could identify and treat all HIV-infected people
immediately after infection, the HIV/AIDS epidemic would eventually disappear.
Such a radical solution is currently unrealistic. In reality, not all people get tested, especially when they fear stigma
and discrimination. Thus, not all HIV-infected individuals are known. Of those HIV-positive individuals for whom the
diagnosis is known, not all of them have access to therapy, agree to be treated, or are taking therapy effectively.
Some on effective treatment will stop, and in others, the development of resistance will lead to treatment failure.
Furthermore, resources are limited: should we provide drugs to asymptomatic HIV-infected individuals without
indication for treatment according to guidelines in order to prevent HIV transmission at the risk of diverting
funding from sick patients in urgent need?
In fact, the preventive potential of anti-HIV drugs is unknown. Modellers have tried to fill the gap, but models differ
depending on assumptions that are strongly debated. Further, indications for antiretroviral treatments expand; in places
like Vancouver and San Francisco, the majority of HIV-positive individuals are now under treatment, and the incidence
of new HIV infections has recently fallen. However, correlation does not necessarily imply causation. Finally, studies in
couples where one partner is HIV-infected also appear to show that treatment reduces the risk of transmission.
More definite studies, where a number of communities are randomized to either receive the “test-and-treat”
approach or continue as before, are now in evaluation by funding agencies. Repeated waves of testing would
precisely measure the incidence of HIV infection. Such trials face formidable logistical, practical and ethical
obstacles. However, without definitive data, the intuitive appeal of “test-and-treat” is unlikely to translate into action
on a global scale. In the meantime, based on the available evidence, we must strive to provide treatment to all
those in medical need under the current medical guidelines. This will lead to a decrease in HIV transmission while
“test-and-treat” is fully explored in prospective clinical trials.
Review
Approximately 2.7 million new HIV infections were diag-
nosed in 2009, mostly in resource-poor countries. In
2009, the estimated number of new HIV infections was
approximately 21% lower than at the epidemic’s peak 12
years earlier. As a result of the combined effect of
increased longevity of treated patients and decrease of
new infections, prevalence is stabilizing [1].
Highly active antiretroviral therapy (HAART) has sub-
stantially reduced AIDS-related hospital admissions and
death rates [2-5]. In the past decade, HAART has become
simpler, better tolerated, less toxic, more effective and
less expensive. There is evidence for an increase in com-
plications in untreated individuals, even at relatively high
CD4 T cell counts [6,7]. As a consequence, indications
for HAART have expanded to include most HIV-infected
patients regardless of their CD4 cell counts [8-10].
In contrast to the proven individual benefits of
HAART, its preventive role has been analyzed less. Only
in recent years has the expansion of HAART been con-
sidered as a tool to limit the growth of the HIV epidemic
[11], in addition to the classical preventive measures,
such as condoms or clean needles for injecting drug
users (IDUs). The viral load correlates with the rate of
heterosexual [12] and mother to child transmission [13].
Since HAART decreases viral load in the blood and in
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HIV transmission.
This article represents the authors’ view, expressed in
a plenary talk given at the XVIII International AIDS
Conference (AIDS 2010) in Vienna, Austria. The most
important evidence regarding the preventive effect of
the treatment of HIV infection is highlighted, without
attempting to perform a comprehensive review.
Most relevant available evidence
Mother to child transmission
Although the biology of HIV sexual transmission is very
different to that of mother to child transmission
(MTCT), the use of antiretroviral drugs in this setting as
ap r e v e n t i v et o o lw a so n eo ft h ef i r s ta n dm o r ep o w e r f u l
pieces of evidence for the effectiveness of this strategy. In
the ACTG076 trial published in 1994, zidovudine was
administered to the mother during pregnancy and labour,
and to the newborn during the first four weeks of life.
MTCT fell from 25.5% to 8.3% [16].
Since then, using antiretrovirals (ARVs) has reduced
transmission to less than 1% [13]. ARVs reduce MTCT
mainly by decreasing maternal viral load in the blood and
genital secretions. An additional mechanism of protection
is infant prophylaxis, because antiretroviral drugs cross the
placenta. This results in adequate systemic drug levels in
the infant during the passage through the birth canal, a
time of intensive exposure to HIV [17]. In developed
countries, treatment with HAART is now the standard of
care in all HIV-positive pregnant women, given its high
effectiveness in preventing MTCT.
Studies in serodiscordant couples
Heterosexual transmission is the main route of HIV
spread worldwide. Coinciding with ACTG 076, Musicco
et al published the results of zidovudine monotherapy in
preventing HIV transmission among 436 serodiscordant
c o u p l e sw h e r et h em a l ep a r t n e rw a sH I Vp o s i t i v e .T h e
rate of transmission from zidovudine-treated men was
lower than from untreated men (relative risk, 0.5; 95%
confidence interval, 0.1 to 0.9) [18]. More recently, Don-
n e l la n dc o l l e a g u e s[ 1 9 ]c o m p a r e dt h eH I Vi n c i d e n c e
rate before and after the initiation of HAART in such
couples. HIV incidence was 2.24 per 100 person-years
before starting HAART (102 transmission events) and
0.37 per 100 person-years after starting HAART (single
transmission event), representing a 12-fold reduction in
transmission. As expected, most of the transmission
events occurred in couples in which the index case had a
high viral load.
In another study from Spain [20], 476 serodiscordant
heterosexual couples were recruited between 1989 and
2008. The only risk factor for the HIV-negative member
of the couple was exposure to the HIV-infected partner.
At enrolment, when the index member was on HAART,
none of the partners were infected, compared with 9.2%
of the partners of untreated patients. During the follow-
up period, there was no HIV transmission in couples
where the index case was on HAART.
Although these studies provide valuable information,
they should not be overestimated. Most of them have ser-
ious limitations. For example, it is not possible to ensure
that couples are totally monogamous and thus not poten-
tially exposed to other sources of HIV acquisition. Outside
the context of serodiscordant couples and MTCT, little
information is available on the preventive effect of
HAART. In particular, controlled studies in men having
sex with men and in intravenous drug users are not avail-
able, but the introduction and recent expansion of
HAART provides opportunities for counting new HIV
infections before and after HAART (so-called “ecological”
studies) in all transmission groups.
Ecological studies
Although a cause-effect relationship is difficult to prove,
ecological studies have correlated the expansion of
H A A R Ti nag i v e np o p u l a t i o na n dt h en u m b e ro fn e w
HIV diagnoses. The most relevant have been performed in
high-income countries, where HAART has not only
expanded, but has also become more effective. In a recent
study from Switzerland performed with participants of the
Swiss HIV Cohort Study, the proportion of patients with
undetectable viral load progressively increased (Figure 1).
Theoretically, as a consequence of HAART expansion and
of the increased effectiveness of treatment, the total
a m o u n to fv i r u si nag i v e np o p u l a t i o n( " t h ec o m m u n i t y
viral load”) decreases, as does the number of potentially
infective patients.
In British Columbia, Canada, Montaner and colleagues
showed an inverse correlation between the expansion of
HAART and the number of newly discovered HIV infec-
tions [21] (Figure 2). A significant increase in the number
of patients on HAART was observed between 1996 and
1999, and this was associated with a reciprocal decrease
in the number of new diagnoses. Between 1999 and 2003,
the number of treated patients stayed relatively stable,
and the same was true of new HIV diagnoses.
Although the biology of blood-borne transmission and
sexual transmission differs, the correlation of the com-
munity viral load and the HIV transmission rate was
particularly suggestive in a cohort of IDUs [22], where
all the HIV-negative participants of the cohort were
screened for HIV every six months. The average viral
load was determined in the HIV-positive participants of
the cohort. The authors found a statistically significant
correlation between the reduction of the average viral
load and the HIV incidence rate. However, it should be
noted that this correlation was especially marked in the
1990s following the rapid initial expansion of HAART
and less marked more recently.
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mostly by men who have sex with men (MSM), Das Dou-
glas and colleagues also studied the correlation of the
“community viral load” and new HIV diagnoses[23]. The
mean community viral load declined between 2004 and
2008 secondary to HAART expansion, and correlated
with a parallel decrease in the number of new diagnoses
(from 798 in 2004 to 434 in 2008). A trend was also
found between community viral load and HIV incidence,
but this correlation was not statistically significant.
Cowan et al showed that in Denmark, more than 80%
of infected MSM are on HAART, and more than 85% of
these have an undetectable viral load [24]. Despite an
increase of unprotected anal intercourse in the MSM
population, the number of newly discovered HIV infec-
tions remained stable in this group, suggesting a lower
rate of transmission per unprotected sex act. This
decrease in transmission could be explained by the high
HAART coverage of the MSM population, with the
undiagnosed or untreated individuals being responsible
for most of the new transmission events [24].
In many of these locations, the decrease in HIV trans-
mission coincided with an increase in other sexually trans-
mitted infections (STIs), particularly syphilis [21,23]. STI
incidence is an indirect indicator of unsafe sex practices;
in addition, ulcerative STIs favour the transmission of
HIV. This apparent contradiction - an increase in unsafe
sex and in the number of potentially infectious HIV posi-
tive individuals due to improved survival, contrasting with
a decreasing HIV incidence - is easily resolved when we
assume that HIV treatment reduces infectivity for HIV but
not, of course, for syphilis and gonorrhoea.
Most of the ecological studies have analyzed the correla-
tion between the proportion of HIV-infected people trea-
ted with HAART, and the number of newly diagnosed
HIV infections (new HIV diagnoses). However, new HIV
diagnoses do not necessarily equal new (or recent) HIV
infections: many of these new diagnoses may represent
older infections. To better correlate the reduction in the
community viral load and HIV transmission, recent infec-
tions should be counted, but information on acquisition of
infection is usually lacking. This situation could be
improved through the widespread use of laboratory tools,
such as the quantitative detection of HIV-RNA in serone-
gative patients, the use of “de-tuned” antibody tests (where
antibodies of lower avidity as typically present in recent
infections are not recorded as “positive” [25]), or through
the analysis of band patterns of immunoblots [26].
Figure 1 Viral load categories for participants of the SHCS in Switzerland. Adapted from Ledergerber et al, presented at CROI 2010 (with
permission). Viral load categories: Stably suppressed: Three consecutive HIV-1 RNA values below detection limit (<50 copies/mL). Improving: A
detectable followed by two undetectable values. Unstable: a) Detectable - undetectable - detectable; or b) Undetectable - detectable -
undetectable. Failing: An undetectable followed by two detectable values. Stable failure: Three consecutive detectable viral load values
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A clinical trial providing definitive evidence of the pre-
ventive role of antiretroviral therapy in HIV transmission
faces numerous obstacles that will be discussed later in
this article. It is much cheaper and faster to model the
preventive effects of potential interventions, such as
increase in HAART coverage at different levels. However,
the results of mathematical models depend on the
assumptions taken and these assumptions differ greatly
between modellers. A complete enumeration or analysis
of the numerous models published for HIV transmission
and treatment is beyond the objective of this article.
However, it is instructive to show the extreme results
according to the assumptions taken. In the most opti-
mistic scenario, Granich and colleagues [27] concluded
that with universal testing of the whole population at
regular intervals, and immediate antiretroviral treatment
for the infected patients, new infections could be vir-
tually eliminated in South Africa within 10 years. In
more pessimistic scenarios, behavioural disinhibition of
infected people following the expansion of HAART
could counteract any potential benefit and the epidemic
would continue growing [28,29].
Lima and colleagues built a mathematical model to
investigate different HAART coverage scenarios (50%,
60%, 75% and 100%) of those medically eligible to
receive HAART under the 2008 IAS-USA guidelines in
British Columbia, Canada [30]. A higher coverage sce-
nario was calculated to cause a rapid initial fall in new
infections followed by a gradual further decrease. Higher
coverage caused initial excess costs, but the consequent
prevention of new infections would save resources, so
that HAART expansion would actually save money over
a period of 50 years or so. With the new updated 2009
IAS-USA guidelines [9], the averted infections and the
economic impact would be even more significant.
Limitations of the “test-and-treat” approach
Impact of undiagnosed individuals on HIV transmission
Many new infections originate from persons who are
HIV positive but undiagnosed. These patients are not
receiving antiretroviral drugs and they can substantially
Ever IDU: Ever injecting drug user
Figure 2 Number of patients active on HAART and newly discovered HIV in Bristish Columbia, Canada. Adapted from Montaner et al,
Lancet 2010,376(9740):532-539 (with permission).
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cannot achieve its full potential without expansion of
testing. In addition, several researchers have found evi-
dence of clusters of recently acquired infections in high-
income countries [31,32], suggesting that a substantial
proportion of transmission events originate from per-
sons who are themselves recently infected. Depending
on the screening test used, some of these persons may
test falsely negative. “Test-and-treat” programmes must
plan for this contingency, perhaps starting with two
waves of testing a few months apart, and using contact
tracing to find persons who were exposed to recent
seroconverters.
Expanded testing
To identify most or all HIV-infected individuals in a
population, testing must increase. However, acceptability
of HIV testing is highly variable among countries, mostly
related to the fear of stigma. This issue has been exam-
ined by a random sample of persons approached and
offered HIV testing in 12 countries, including nine coun-
tries in sub-Saharan Africa (representing 18% of the epi-
demic in Africa). Results showed striking differences:
whereas more than 60% agreed to be tested and received
the results of HIV tests in the Dominican Republic and
Swaziland, this proportion fell to 10% in Democratic
Republic of Congo, and to 7% in Ethiopia [33].
From testing to retention in care
Patients, once they have been identified as HIV infected,
do not all have CD4 cell count tests performed. If they
have CD4 cell count tests, not all eligible patients will start
HAART; HAART will not be effective in all who have this
treatment; and some patients with effective treatment will
discontinue. This cascade is convincingly presented in the
real-life description of an urban clinic in Durban, South
Africa [34]. After identifying 3400 people living with HIV,
82% were enrolled, of whom 69% had CD4 cell tests, but
only 39% of eligible patients were started on HAART
(Figure 3). Bendavid and colleagues concluded that
increasing linkages to care and preventing loss to follow
up could provide nearly twice the benefits of universal
testing and treatment alone [35]. If patients are not
retained in care after HAART initiation, the “test-and-
treat” strategy will have little impact on prevention.
Impact of HAART on risk behaviour
HAART improves health and well-being and has changed
the perception of HIV infection [36], considered now to
be a manageable chronic disease. This may lead some
patients to abandon safe sex, a phenomenon called risk
compensation [37,38]. Risk compensation has been con-
sidered important enough in some mathematical models
to counterbalance any positive impact of HAART expan-
sion on transmission [28,29]. However, while the prob-
ability of transmission from a person on HAART with
undetectable viremia cannot be quantified, it is probably
low; indeed, only a single case report has so far been pub-
lished [39]. Thus, even if risk compensation did occur, its
effect on HIV transmission would be blunted by effective
HAART in adherent patients. In addition, it should be
noted that no risk compensation has been observed so
far in the trials evaluating circumcision and topical
microbicides [40-43].
Access to HAART and costs
Expansion of HAART will increase costs in the short run,
i.e., during the first five to 20 years of the expansion.
Later on, if expansion indeed reduces transmission, there
are potential savings. The balance between investment
and return depends on assumptions regarding costs of
expanded testing, monitoring, drugs, uptake and efficacy
of treatment, and changes in risk behaviour (among
others).
Opinions regarding these assumptions vary widely. For
example, Johnston and colleagues have estimated that
over 30 years, a HAART expansion scenario from 50% to
75% of clinically eligible individuals would be associated
with a net benefit of US$900 million in British Columbia,
Canada [44]. On the other hand, in the wake of the eco-
nomic recession of 2008, global budgets for antiretroviral
treatment have stagnated. Patients who are already on
treatment will need drugs for many years, while others,
with deepening immune deficiency, will add to the num-
bers of those who need treatment. It will be a challenge
to fulfil that need during the next 10 years, and perhaps
unrealistic to plan for expansion of treatment in the hope
of a hypothetical benefit in a generation or two.
Perspectives: the research agenda
HPTN052 is a randomized study to evaluate HAART in
preventing sexual transmission in serodiscordant couples.
This study has been fully recruited since May 2010, and it
includes 1750 couples where the infected partners have
CD4 counts of 350 to 550 cells/mm
3. In the intervention
group, HAART is started at enrolment, while in the con-
trol group, HAART is started according to the local indi-
cation in the country where the study takes place. The
endpoints of the study are the number of transmission
events. Planned follow up will last at least five years; thus
the first results are expected in 2015.
This is a well-designed, pioneering study, but in the gen-
eral population, the methodology used in HPTN052 is not
applicable. It would entail: (1) testing a whole population;
(2) randomizing all HIV-positive people to either immedi-
ate or delayed treatment; and (3) following all sexual part-
ners to check whether infection occurs. As stated in the
section of serodiscordant couples, monogamy cannot be
assumed in these types of studies. A so-called “cluster ran-
domized trial” i sam o r er e a l i s t i cp r o p o s i t i o n .I ns u c ha
trial, the unit of randomization is not the individual, but a
community of individuals, for example, a town.
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include approximately 30 clusters. An attempt will be
made to screen all inhabitants of all clusters for HIV. In
the intervention clusters, all who screen HIV positive
will be treated, while in the control clusters, HAART
will be administered only to patients with treatment
indications according to local guidelines. The primary
endpoint will be the number of incident HIV infections
as measured by repetitive six-monthly screening. Several
secondary endpoints would be considered, such as
acceptability and the results of widespread testing, beha-
vioural modifications, cost and cost effectiveness, and
morbidity and mortality in the HIV-positive population.
A study of this type represents a priority in AIDS pre-
vention research for the years to come, but it faces formid-
able obstacles. To start with, universal testing must be
done in a way that avoids pressure, stigma and discrimina-
tion; this is not an easy undertaking. Success depends on
maintaining a meaningful difference between intervention
and control clusters. But in intervention clusters, not all
will be screened, and of those found to be seropositive,
not all will be treated. Of those who are treated, not all
will have effective treatment, and of those with effective
treatment, some will drop out and stop taking the medica-
tion. Meanwhile, in the control clusters, some are already
on treatment, and many others will start during the trial
as immune deficiency deepens and indications for treat-
ment expand.
Other prevention methods, such as condoms and
abstinence today and perhaps circumcision and microbi-
cides tomorrow, will be used in both types of clusters.
All these factors are expected to obscure the differences
between intervention and control clusters at the risk of
making the study inconclusive.
Such a trial has been proposed to the National Asso-
ciation for AIDS Research in France, and has been
Figure 3 Attrition in a HAART initiation study. Study enrolment, HIV test results, CD4 cell count results and HAART initiation in two clinics of
Durban, South Africa. Adapted from Bassett et al, AIDS 2010, 24(Suppl 1):S37-S44 (with permission).
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trial demonstrates a benefit, public health authorities
will need to evaluate the potential advantage of local
decrease in HIV transmission over the financial cost of
this strategy [45].
Conclusions
In conclusion, a growing body of circumstantial evi-
dence suggests an important preventive role for
HAART. While waiting for results of definitive trials,
maximum efforts must be made to ensure that every
patient with clinical indication is treated. In resource-
poor settings, providing treatment for all patients with
C D 4c o u n t so fl e s st h a n3 5 0c e l l s / m m
3 already repre-
sents a considerable challenge. Ensuring equitable access
to testing, counselling and HAART in every country
according to national guidelines would at least represent
a first important step towards optimizing the prevention
effect of antiretroviral drugs.
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